3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Cardiotoxicity
2
Breast Neoplasms
2
Renal Insufficiency, Chronic
1
Kidney Neoplasms
1
Heart Failure
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
14
Nivolumab
10
Ipilimumab
10
Axitinib
6
cabozantinib
5
belzutifan
5
Radiosurgery
5
atezolizumab
4
Sunitinib
4
palbociclib
3
lenvatinib
3
Surveys and Questionnaires
3
Radiotherapy
3
Pluvicto
3
Everolimus
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
pazopanib
2
cemiplimab
2
Therapeutics
2
Methods
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
trebananib
1
toripalimab
1
tocilizumab
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
empagliflozin
×
1 year
×
Clear all
NCT06818305
2025-12-11
EmFin-Nx
Jinling Hospital, China
Phase 2
Terminated
10 enrolled